- Home
- BIAF vs EQ Comparison
BIAF vs EQ Comparison
Compare BIAF & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- EQ
- Stock Information
- Founded
- BIAF 2014
- EQ 2017
- Country
- BIAF United States
- EQ United States
- Employees
- BIAF N/A
- EQ N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- EQ Health Care
- Exchange
- BIAF Nasdaq
- EQ Nasdaq
- Market Cap
- BIAF 21.4M
- EQ 24.8M
- IPO Year
- BIAF 2022
- EQ 2018
- Fundamental
- Price
- BIAF $1.24
- EQ $0.72
- Analyst Decision
- BIAF Strong Buy
- EQ Buy
- Analyst Count
- BIAF 1
- EQ 2
- Target Price
- BIAF $6.00
- EQ $5.00
- AVG Volume (30 Days)
- BIAF 102.5K
- EQ 304.3K
- Earning Date
- BIAF 11-14-2024
- EQ 11-13-2024
- Dividend Yield
- BIAF N/A
- EQ N/A
- EPS Growth
- BIAF N/A
- EQ N/A
- EPS
- BIAF N/A
- EQ N/A
- Revenue
- BIAF $9,367,785.00
- EQ $45,914,000.00
- Revenue This Year
- BIAF $302.41
- EQ N/A
- Revenue Next Year
- BIAF $15.00
- EQ N/A
- P/E Ratio
- BIAF N/A
- EQ N/A
- Revenue Growth
- BIAF 2813.87
- EQ 7.70
- 52 Week Low
- BIAF $1.20
- EQ $0.48
- 52 Week High
- BIAF $3.62
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- BIAF 36.67
- EQ 40.86
- Support Level
- BIAF $1.21
- EQ $0.66
- Resistance Level
- BIAF $1.37
- EQ $0.77
- Average True Range (ATR)
- BIAF 0.08
- EQ 0.08
- MACD
- BIAF 0.01
- EQ -0.01
- Stochastic Oscillator
- BIAF 17.50
- EQ 26.09
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.